Oxaliplatin
Based on 226 publication(s) in Google Scholar
Oxaliplatin is a DNA synthesis inhibitor. Oxaliplatin causes DNA crosslinking damage, prevents DNA replication and transcription and induces apoptosis. Oxaliplatin can be used for cancer research.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté: 99.65%
- CAS No.: 61825-94-3
- Formule: C8H14N2O4Pt
- Masse moléculaire:397.29
-
Stockage:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Oxaliplatin
More- Signal Transduct Target Ther. 2025 Dec 15;10(1):406. [Abstract]
- Signal Transduct Target Ther. 2022 Sep 12;7(1):317. [Abstract]
- Signal Transduct Target Ther. 2021 May 28;6(1):188. [Abstract]
- Nat Med. 2024 Mar;30(3):749-761. [Abstract]
- Nat Med. 2019 Sep;25(9):1428-1441. [Abstract]
- Cancer Cell. 2026 Apr 13;44(4):809-830.e11. [Abstract]
- Cancer Cell. 2026 Mar 9;44(3):658-675.e12. [Abstract]
- Cancer Cell. 2025 Sep 25:S1535-6108(25)00393-9. [Abstract]
- Mol Cancer. 2024 Jan 10;23(1):12. [Abstract]
- Nat Cancer. 2022 Sep;3(9):1052-1070. [Abstract]
- Adv Mater. 2026 Mar 15:e22617. [Abstract]
- Gastroenterology. 2021 Nov;161(5):1601-1614.e23. [Abstract]
- Nat Mach Intell. 2026 Mar 4;8(3):351-371.
- Drug Resist Updat. 2024 Dec 3:78:101179. [Abstract]
- JAMA Oncol. 2022 Jan 1;8(1):e215445. [Abstract]
- Cell Mol Immunol. 2023 Jan;20(1):51-64. [Abstract]
- Nat Cell Biol. 2024 Aug;26(8):1346-1358. [Abstract]
- Cell Host Microbe. 2025 Jun 11;33(6):941-956.e10. [Abstract]
- Cancer Res. 2018 Oct 1;78(19):5586-5599. [Abstract]
- Nat Commun. 2026 May 7. [Abstract]
- Nat Commun. 2025 May 30;16(1):5006. [Abstract]
- Nat Commun. 2023 Sep 25;14(1):5534. [Abstract]
- Cell Death Differ. 2026 Jun 3. [Abstract]
- Adv Sci (Weinh). 2026 Feb 3:e16660. [Abstract]
- Adv Sci (Weinh). 2025 May 8:e2500271. [Abstract]
- Adv Sci (Weinh). 2025 Jan 31:e2408845. [Abstract]
- Adv Sci (Weinh). 2024 Dec 16:e2407387. [Abstract]
- Adv Sci (Weinh). 2024 Jul;11(26):e2308690. [Abstract]
- Adv Sci (Weinh). 2023 Sep;10(27):e2302640. [Abstract]
- Adv Sci (Weinh). 2023 Sep;10(25):e2301088. [Abstract]
- Chem Eng J. 2025 Jun 6.
- Chem Eng J. 2023 Nov 17, 147466.
- Biomaterials. 2024 Oct:310:122625. [Abstract]
- J Exp Clin Cancer Res. 2025 Aug 19;44(1):245. [Abstract]
- J Exp Clin Cancer Res. 2022 Oct 14;41(1):302. [Abstract]
- J Exp Clin Cancer Res. 2021 Sep 22;40(1):297. [Abstract]
- J Exp Clin Cancer Res. 2017 Sep 22;36(1):131. [Abstract]
- J Nanobiotechnology. 2025 May 16;23(1):352. [Abstract]
- J Nanobiotechnology. 2022 Nov 3;20(1):468. [Abstract]
- Cell Discov. 2022 Sep 14;8(1):92. [Abstract]
- Redox Biol. 2026 Mar:90:104043. [Abstract]
- Redox Biol. 2024 May 23:73:103207. [Abstract]
- J Control Release. 2021 Apr 10:332:448-459. [Abstract]
- Gut Microbes. 2024 Jan-Dec;16(1):2333790. [Abstract]
- MedComm (2020). 2024 Jul 24;5(8):e665. [Abstract]
- Cell Rep Med. 2026 May 19;7(5):102757. [Abstract]
- Cell Rep Med. 2026 Mar 17;7(3):102635. [Abstract]
- J Immunother Cancer. 2026 Jan 8;14(1):e012121. [Abstract]
- J Immunother Cancer. 2025 Nov 19;13(11):e012652. [Abstract]
- Cell Rep Med. 2025 Apr 2:102053. [Abstract]
- J Immunother Cancer. 2022 Aug;10(8):e004006. [Abstract]
- J Exp Med. 2018 Jan 2;215(1):115-140. [Abstract]
- Pharmacol Res. 2025 Dec:222:108027. [Abstract]
- Pharmacol Res. 2024 May 9:204:107208. [Abstract]
- Cancer Lett. 2026 Jan 28:638:218156. [Abstract]
- Cancer Lett. 2025 Sep 25:634:218064. [Abstract]
- Cancer Lett. 2025 Feb 8:217544. [Abstract]
- Cancer Lett. 2023 Sep 1:571:216338. [Abstract]
- Cancer Lett. 2022 Nov 28:549:215837. [Abstract]
- Cancer Lett. 2020 Apr 28;476:67-74. [Abstract]
- Int J Biol Sci. 2022 May 21;18(9):3747-3761. [Abstract]
- Cell Death Dis. 2026 Mar 18;17(1):320. [Abstract]
- Adv Healthc Mater. 2025 Oct 13:e01791. [Abstract]
- Cell Death Dis. 2025 May 14;16(1):379. [Abstract]
- Cell Death Dis. 2025 Apr 5;16(1):253. [Abstract]
- Cell Death Dis. 2025 Apr 14;16(1):293. [Abstract]
- Cell Death Dis. 2025 Jan 18;16(1):28. [Abstract]
- Cell Death Dis. 2024 Nov 5;15(11):794. [Abstract]
- Cell Death Dis. 2022 Oct 4;13(10):848. [Abstract]
- Acta Biomater. 2022 May;144:132-141. [Abstract]
- Cell Death Dis. 2021 Oct 6;12(10):911. [Abstract]
- Cell Death Dis. 2019 Aug 13;10(8):615. [Abstract]
- Cell Death Dis. 2018 May 22;9(6):591. [Abstract]
- Proc Natl Acad Sci U S A. 2017 Mar 7;114(10):E1825-E1832. [Abstract]
- Nano Res. 2025 Oct.
- Cell Commun Signal. 2025 Nov 27;23(1):513. [Abstract]
- Cell Commun Signal. 2025 Jun 13;23(1):280. [Abstract]
- Dev Cell. 2026 Jun 10.
- View. 2023 Nov 15.
- Acta Pharmacol Sin. 2023 Jan;44(1):178-188. [Abstract]
- Acta Pharmacol Sin. 2021 Jan;42(1):108-114. [Abstract]
- Phytomedicine. 2025 Sep:145:157039. [Abstract]
- Phytomedicine. 2025 Apr:139:156465. [Abstract]
- Phytomedicine. 2024 Jul 25:133:155906. [Abstract]
- Phytomedicine. 2024 Jan:123:155169. [Abstract]
- ACS Appl Mater Interfaces. 2026 Feb 11;18(5):7900-7909. [Abstract]
- Apoptosis. 2026 Mar 19;31(3):102. [Abstract]
- Neoplasia. 2025 Feb 11:61:101138. [Abstract]
- J Transl Med. 2025 Oct 16;23(1):1112. [Abstract]
- Biomed Pharmacother. 2025 Aug 19:191:118481. [Abstract]
- Biomed Pharmacother. 2024 Nov:180:117576. [Abstract]
- Biomed Pharmacother. 2024 Jun 4:176:116826. [Abstract]
- Biomed Pharmacother. 2024 May 16:175:116743. [Abstract]
- Biomed Pharmacother. 2023 Jul:163:114751. [Abstract]
- Biomed Pharmacother. 2018 Jul:103:729-737. [Abstract]
- Oncogene. 2025 Sep 18. [Abstract]
- Oncogene. 2024 Nov;43(48):3532-3544. [Abstract]
- Cell Chem Biol. 2020 Nov 19;27(11):1359-1370.e8. [Abstract]
- Cell Rep. 2023 Mar 20;42(3):112275. [Abstract]
- Cell Rep. 2021 Nov 30;37(9):110069. [Abstract]
- J Med Chem. 2021 Jul 8;64(13):9271-9278. [Abstract]
- J Med Chem. 2020 Aug 13;63(15):8380-8387. [Abstract]
- Int J Nanomedicine. 2024 Jan 6:19:171-188. [Abstract]
- Int J Nanomedicine. 2019 Dec 2;14:9377-9393. [Abstract]
- Oncogenesis. 2025 Nov 7;14(1):39. [Abstract]
- Mol Med. 2025 Mar 25;31(1):115. [Abstract]
- J Cell Biol. 2023 Jan 2;222(1):e202202110. [Abstract]
- Cell Biosci. 2025 Jul 4;15(1):95. [Abstract]
- Cell Biosci. 2024 Jan 20;14(1):12. [Abstract]
- Ecotoxicol Environ Saf. 2025 Nov 15:307:119433. [Abstract]
- Biomater Adv. 2026 May:182:214726. [Abstract]
- Biomater Adv. 2025 Dec 11:181:214656. [Abstract]
- Cancer Cell Int. 2025 Oct 15;25(1):357. [Abstract]
- Cancer Cell Int. 2025 Feb 27;25(1):70. [Abstract]
- Eur J Med Chem. 2021 Jan 15;210:113080. [Abstract]
- Int J Mol Med. 2026 Jan;57(1):4. [Abstract]
- Biosensors (Basel). 2026 Mar 25;16(4):189. [Abstract]
- Biochem Pharmacol. 2025 Jul 12:241:117159. [Abstract]
- Mol Cancer Ther. 2026 Jun 13. [Abstract]
- Mol Cancer Ther. 2025 Dec 4. [Abstract]
- Mol Cancer Ther. 2020 Mar;19(3):906-919. [Abstract]
- J Ethnopharmacol. 2024 Mar 25:322:117598. [Abstract]
- Mar Drugs. 2023 Nov 21;21(12):600. [Abstract]
- Mol Ther Oncol. 2025 Nov 22;33(4):201098. [Abstract]
- Cells. 2026 Feb 28;15(5):430. [Abstract]
- Cells. 2022 Nov 11;11(22):3561. [Abstract]
- Food Hydrocoll Health. 2025 Jun.
- Commun Biol. 2024 Dec 3;7(1):1612. [Abstract]
- Precis Clin Med. 2026 Mar 14;9(2):pbag009. [Abstract]
- Int J Mol Sci. 2026 Mar 13;27(6):2646. [Abstract]
- Int J Mol Sci. 2025 Mar 21;26(7):2848. [Abstract]
- Biol Direct. 2024 Sep 11;19(1):79. [Abstract]
- Int J Mol Sci. 2023 Jun 8;24(12):9899. [Abstract]
- Int J Oncol. 2022 Nov;61(5):139. [Abstract]
- Int Immunopharmacol. 2024 May 10:134:112197. [Abstract]
- Eur J Pharmacol. 2024 Jul 5:974:176538. [Abstract]
- Int J Cancer. 2020 Mar 15;146(6):1700-1716. [Abstract]
- Mol Oncol. 2026 Jun 5. [Abstract]
- Mol Oncol. 2020 Nov;14(11):2894-2919. [Abstract]
- Cancers (Basel). 2023 Sep 6;15(18):4442. [Abstract]
- Clin Epigenetics. 2022 Dec 24;14(1):184. [Abstract]
- Cancers (Basel). 2022 Apr 6;14(7):1848. [Abstract]
- ACS Omega. 2025 Oct 30;10(44):52931-52943. [Abstract]
- Pharm Res. 2025 Nov 18. [Abstract]
- Cancer Sci. 2023 Jul;114(7):2951-2960. [Abstract]
- FEBS J. 2026 Mar 20. [Abstract]
- FEBS J. 2025 Apr 22. [Abstract]
- Bioengineered. 2022 Mar;13(3):6688-6697. [Abstract]
- J Mol Med (Berl). 2019 Aug;97(8):1183-1193. [Abstract]
- Transl Oncol. 2025 Oct:60:102491. [Abstract]
- iScience. 2024 Dec 4;27(12):111437. [Abstract]
- Neurochem Int. 2025 May:185:105961. [Abstract]
- Front Cell Neurosci. 2017 Jul 21:11:219. [Abstract]
- Sci Rep. 2026 May 31. [Abstract]
- Sci Rep. 2026 Apr 3;16(1):17440. [Abstract]
- Sci Rep. 2025 Sep 29;15(1):33421. [Abstract]
- Sci Rep. 2024 Nov 29;14(1):29661. [Abstract]
- Sci Rep. 2023 Sep 1;13(1):14359. [Abstract]
- Oncol Rep. 2020 Feb;43(2):405-414. [Abstract]
- Sci Rep. 2016 Dec 1;6:38267. [Abstract]
- Clin Immunol. 2023 Nov:256:109774. [Abstract]
- Cancer Res Treat. 2023 Oct;55(4):1077-1086. [Abstract]
- ACS Pharmacol Transl Sci. 2026 Mar 28;9(4):1010-1020. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2025 Apr 4:119953. [Abstract]
- ACS Pharmacol Transl Sci. 2024 Nov 12;7(12):3935-3944. [Abstract]
- Biochim Biophys Acta Mol Cell Res. 2024 Sep 14:119846. [Abstract]
- Digestion. 2025 Mar 27:1-19. [Abstract]
- Heliyon. 2023 Jun 1;9(6):e16872. [Abstract]
- Heliyon. 2022 Oct 30;8(11):e11305. [Abstract]
- Exp Cell Res. 2020 Aug 1;393(1):112054. [Abstract]
- J Gastroenterol Hepatol. 2026 Mar 12. [Abstract]
- BMC Cancer. 2025 Dec 31. [Abstract]
- BMC Cancer. 2024 Oct 13;24(1):1272. [Abstract]
- Stem Cells Int. 2021 Nov 23:2021:1075481. [Abstract]
- Front Oncol. 2021 Jul 13:11:704042. [Abstract]
- Dalton Trans. 2020 May 7;49(17):5703-5710. [Abstract]
- Pathol Res Pract. 2026 May:281:156400. [Abstract]
- Pathol Res Pract. 2025 May 21:271:156033. [Abstract]
- Mol Carcinog. 2025 Apr 13. [Abstract]
- J Inorg Biochem. 2024 Aug 19:260:112702. [Abstract]
- Mol Carcinog. 2017 Dec;56(12):2692-2705. [Abstract]
- Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr;398(4):4393-4407. [Abstract]
- Hum Cell. 2023 Jan;36(1):258-275. [Abstract]
- Mol Biol Rep. 2025 Apr 15;52(1):394. [Abstract]
- J Cancer Res Clin Oncol. 2024 May 8;150(5):244. [Abstract]
- PLoS One. 2026 Feb 10;21(2):e0341971. [Abstract]
- Int J Immunopathol Pharmacol. 2025 Jan-Dec:39:3946320251338662. [Abstract]
- Photodiagnosis Photodyn Ther. 2022 Dec:40:103082. [Abstract]
- World J Gastrointest Oncol. 2025 Aug 15;17(8):108535. [Abstract]
- In Vitro Model. 2025 Mar 5;4(1):31-44. [Abstract]
- Biomol Biomed. 2025 Mar 7;25(4):857-868. [Abstract]
- Biochem Biophys Res Commun. 2024 May 28:710:149895. [Abstract]
- Biochem Biophys Res Commun. 2023 Jan 1:638:94-102. [Abstract]
- Biochem Biophys Res Commun. 2021 Jul 23:563:1-7. [Abstract]
- Cancer Rep. 2025 Dec;8(12):e70401. [Abstract]
- Biol Pharm Bull. 2019 Jun 1;42(6):900-905. [Abstract]
- Gastroenterol Res Pract. 2021 Jun 17:2021:5960821. [Abstract]
- Biocell. 2026 Jan 23.
- Int J Clin Exp Pathol. 2017;10(3):3033-3042.
- medRxiv. 2026 Apr 18.
- bioRxiv. 2026 Apr 7.
- Res Sq. 2026 Mar 5.
- Res Sq. 2026 Jan 15.
- Patent. US20250320299A1.
- bioRxiv. 2025 Oct 9:2025.10.08.681217. [Abstract]
- bioRxiv. 2025 Sep 17.
- bioRxiv. 2025 Aug 19.
- SSRN. 2025 Jul 7.
- bioRxiv. 2025 Apr 24:2025.04.21.649594. [Abstract]
- Res Sq. 2025 Apr 06.
- bioRxiv. 2025 Feb 22:2025.02.17.638725. [Abstract]
- bioRxiv. 2025 January 16.
- Patent. US20240342225A1
- Res Sq. 2024 Aug 11.
- Res Sq. 2024 Jul 12.
- bioRxiv. 2023 Oct 10.
- SSRN. 2023 Jun 6.
- bioRxiv. 2023 Feb 28.
- Ann Transl Med. 2023 Feb 28;11(4):185. [Abstract]
- Oxid Med Cell Longev. 2023 Feb 16:2023:4772134. [Abstract]
- bioRxiv. 2023 Jan 28.
- Research Square Print. 2022 May.
- Research Square Preprint. 2021 Oct.
- Patent. US10947274.
- Université de Genève. 2020 Sep.
- Tumour Biol. 2016 Jul;37(7):8811-24. [Abstract]
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
Voir tous les produits spécifiques à Isoform DNA/RNA Synthesis
More
Activité biologique
IC50: DNA synthesis[1]
Oxaliplatin (24-72 hours; 2-128 μM; HCC, HCCLM3 and Hep3B cells) inhibits cell growth and induces apoptosis[1].
Oxaliplatin (10 μM; 15-240 mins; CEM cells ) induces primary and secondary DNA lesions, including DNA cross-links (ISC) and DNA-protein cross-links (DPC)[2].
Oxaliplatin (0.01 to 100 μM; 24 hours) potently inhibits bladder carcinoma cell lines RT4 and TCCSUP, ovarian carcinoma cell line A2780, colon carcinoma cell line HT-29, glioblastoma cell lines U-373MG and U-87MG, and melanoma cell lines SK-MEL-2 and HT-144 with IC50 of 11 μM, 15 μM, 0.17 μM, 0.97 μM, 2.95 μM, 17.6 μM, 30.9 μM and 7.85 μM, respectively[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:HCC, HCCLM3 and Hep3B cells
-
Concentration:24, 48 and 72 hours
-
Incubation Time:2, 4, 8, 16, 32, 64 and 128 μM
-
Result:Decreased cell viability in a dose- and time-dependent manner.
-
Cell Line:HCCLM3 and Hep3B cells
-
Concentration:10 μM
-
Incubation Time:24 hours
-
Result:Increased the percentage of apoptotic cells (17.70% for HCCLM3 cells; 21.19% for Hep3B cells).
-
Cell Line:HCCLM3 cells
-
Concentration:10 μM
-
Incubation Time:48 hours
-
Result:Down-regulated the expression of Bcl-2 and Bcl-xL, and increased the expression of Bax.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Nude mice[1]
-
Dosage:5 and 10 mg/kg
-
Administration:Intraperitoneal injection; for 32 days
-
Result:Reduced tumor volume in HCCLM3 tumor xenografts.
Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.
Administration: Oxaliplatin (3, 5, 6 and 10 mg/kg) • i.p. • once
Rats: SD rats
Administration: Oxaliplatin (2 mg/kg) • i.p. • once
Mice: Male CD-1 mice
Administration: Oxaliplatin (10 mg/kg) • i.p. • once
Mice: Male C57BL/6 mice
Administration: Oxaliplatin (3 and 6 mg/kg) • i.p. • once
Mice: Male BALB/c mice
Administration: Oxaliplatin (5 mg/kg) • i.v. • once
Mechanical allodynia: Decreased paw withdrawal threshold (Von Frey test)
Cold allodynia: Decreased paw withdrawal latency (acetone test)
Motor function: No impairment (rotarod test), confirming pain specificity
Administration: Oxaliplatin (2.4 mg/kg) • i.p. • on days 1-3, 6-10, and 13-15
Rats: SD rats
Administration: Oxaliplatin (2 and 4 mg/kg) • i.p. • on days 1, 2, 3, 4, 5
Rats: SD rats
Administration: Oxaliplatin (6 mg/kg) • i.p. • on days 1,3, 5, 7
Rats: SD rats
Administration: Oxaliplatin (2.4, 3.2, and 4 mg/kg) • i.p. • twice weekly for 4.5 weeks
Rats: Wistar rats
Administration: Oxaliplatin (4 mg/kg) • i.p. • twice weekly for 4 weeks
Rats: Wistar rats
Administration: Oxaliplatin (6 mg/kg) • i.p. • once per day for 6 days
Rats: SD rats
Administration: Oxaliplatin (2 mg/kg) • i.v. • once per day for 5 days
Mice: C57BL/6J mice; BALB/c mice; ICR mice
Administration: Oxaliplatin (0.3 and 3 mg/kg) • i.p. • 5 consecutive days, followed by 2 days of rest, for two cycles
Mice: C57BL/6 mice
Administration: Oxaliplatin (3 mg/kg) • i.p. • 3 times per week for 4 weeks
Mice: CD-1 mice
Administration: Oxaliplatin (2.4 mg/kg) • i.p. • 5 consecutive days each week for 2 weeks
Mice: Swiss mice
Administration: Oxaliplatin (6 mg/kg) • i.p. • every 3 days over 6 days
Histological changes: Significant loss of intraepidermal nerve fibers (IENF) in hind paw skin
Mechanical allodynia: Decreased paw withdrawal threshold (Von Frey test)
Cold allodynia: Decreased paw withdrawal latency (acetone test)
Motor function: No impairment (rotarod test), confirming pain specificity
Nerve conduction velocity: Decreased sensory nerve conduction velocity (SNCV); normal motor nerve conduction velocity (MNCV)
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
CAS No. 61825-94-3
-
Appearance Solid
-
Masse moléculaire 397.29
-
Formule C8H14N2O4Pt
-
Color White to off-white
-
SMILES
O=C(O1)C(O[Pt]21[NH2][C@@H]3CCCC[C@H]3[NH2]2)=O
-
Livraison
Room temperature in continental US; may vary elsewhere.
-
Stockage
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (226)
-
Journal Impact Factor
-
Most Recent
-
Signal Transduct Target Ther
Selective depletion of tumor-associated SAMHD1 enhances chemotherapeutic efficacy and antitumor immune responses. [Abstract]2025 Dec 15;10(1):406. PMID: 41392286 -
Signal Transduct Target Ther
Elaiophylin triggers paraptosis and preferentially kills ovarian cancer drug-resistant cells by inducing MAPK hyperactivation. [Abstract]2022 Sep 12;7(1):317. PMID: 36097006 -
Signal Transduct Target Ther
Cyst(e)ine in nutrition formulation promotes colon cancer growth and chemoresistance by activating mTORC1 and scavenging ROS. [Abstract]2021 May 28;6(1):188. PMID: 34045438 -
Nat Med
Prospective observational study on biomarkers of response in pancreatic ductal adenocarcinoma. [Abstract]2024 Mar;30(3):749-761. PMID: 38287168
Oxaliplatin purchased from MedChemExpress. Usage Cited in: Nat Med. 2024 Mar;30(3):749-761. [Abstract]
The relative cell viability of shCtl-, shNDUFB8-, and shCEMIP2-transfected cells was detected by XTT assay after paclitaxel plus gemcitabine treatment (A+G), single-agent 5-Fu (5-FU), and the FOLFIRINOX chemotherapy cocktail [FU+IRI+OXA: 5-FU+Irinotecan (SN-38) +Oxaliplatin (50 nM)] for 48h.
-
Nat Med
2019 Sep;25(9):1428-1441. PMID: 31501614
Oxaliplatin purchased from MedChemExpress. Usage Cited in: Nat Med. 2019 Sep;25(9):1428-1441. [Abstract]
Quantification of CD3+IFN-γ+ T cells in lung lobes taken from urethane-induced primary lung cancer models (n = 5 mice for SD group, n = 6 mice for all the other groups). Three coronal sections containing five pulmonary lobes from each mouse near the maximal diameters are quantified. Each dot represents one view field. A representative result from two independent experiments is shown.
-
Cancer Cell
Dissecting genetic and immune drivers of heterogeneous responses to neoadjuvant immunochemotherapy in gastric cancer. [Abstract]2026 Apr 13;44(4):809-830.e11. PMID: 41720086 -
Cancer Cell
Chemotherapy triggers immune evasion by fostering LEPR+ Kupffer cell differentiation in liver metastases. [Abstract]2026 Mar 9;44(3):658-675.e12. PMID: 41687606 -
Cancer Cell
Single-cell resolution spatial analysis of antigen-presenting cancer-associated fibroblast niches. [Abstract]2025 Sep 25:S1535-6108(25)00393-9. PMID: 41005303 -
Mol Cancer
Organoids derived from patients provide a new opportunity for research and individualized treatment of malignant peritoneal mesothelioma. [Abstract]2024 Jan 10;23(1):12. PMID: 38200517 -
Nat Cancer
Mex3a marks drug-tolerant persister colorectal cancer cells that mediate relapse after chemotherapy. [Abstract]2022 Sep;3(9):1052-1070. PMID: 35773527 -
Adv Mater
Efficacy and Safety Assessment of 5-Fluorouracil, Irinotecan and Oxaliplatin-Loaded Implants in Mouse and Pig Models for Pancreatic Cancer Therapy. [Abstract]2026 Mar 15:e22617. PMID: 41834342 -
Gastroenterology
AGR2-Dependent Nuclear Import of RNA Polymerase II Constitutes a Specific Target of Pancreatic Ductal Adenocarcinoma in the Context of Wild-Type p53. [Abstract]2021 Nov;161(5):1601-1614.e23. PMID: 34303658
Oxaliplatin purchased from MedChemExpress. Usage Cited in: Gastroenterology. 2021 Nov;161(5):1601-1614.e23. [Abstract]
Bar graphs show the GI50 of 5-fluoruracil (48 h), irinotecan (48 h), gemcitabine (48 h), paclitaxel (48 h), and oxaliplatin (48 h) in PDAC cells in combination with bioactive hexapeptides (NTAIYY and PTTIYY) or controls (saline and NTAIYA).
-
-
Drug Resist Updat
CEA-induced PI3K/AKT pathway activation through the binding of CEA to KRT1 contributes to oxaliplatin resistance in gastric cancer. [Abstract]2024 Dec 3:78:101179. PMID: 39644827
Oxaliplatin purchased from MedChemExpress. Usage Cited in: Drug Resist Updat. 2024 Dec 3:78:101179. [Abstract]
Oxaliplatin (100 nM-4 μM; 48 h) inhibits CEAhigh (AGS) and CEA-/lo (xhGC1) gastric cancer cells, with IC50 values of 150 nM and 2.2 μM, respectively.
-
JAMA Oncol
Chemoradiotherapy Plus Induction or Consolidation Chemotherapy as Total Neoadjuvant Therapy for Patients With Locally Advanced Rectal Cancer: Long-term Results of the CAO/ARO/AIO-12 Randomized Clinical Trial. [Abstract]2022 Jan 1;8(1):e215445. PMID: 34792531 -
Cell Mol Immunol
Arsenic trioxide elicits prophylactic and therapeutic immune responses against solid tumors by inducing necroptosis and ferroptosis. [Abstract]2023 Jan;20(1):51-64. PMID: 36447031
Oxaliplatin purchased from MedChemExpress. Usage Cited in: Cell Mol Immunol. 2023 Jan;20(1):51-64. [Abstract]
Comparison of drug (Epirubicin hydrochloride, EPI; Daunorubicin hydrochloride, DNR; Vinorelbine ditartrate, VNR; Oxaliplatin, OXA; Vincristine, VCR; Artemisinin, ART; Colchicine, COL) cytotoxicity to TC1 cells at the indicated doses and time points measured with CCK-8 assays. R.U. (Relative unit) was calculated from the average O.D. values in each condition as the indicator of cell viability (n = 3).
-
Nat Cell Biol
Trafficking circuit of CD8+ T cells between the intestine and bone marrow governs antitumour immunity. [Abstract]2024 Aug;26(8):1346-1358. PMID: 39039181 -
Cell Host Microbe
Bacteroides fragilis promotes chemoresistance in colorectal cancer, and its elimination by phage VA7 restores chemosensitivity. [Abstract]2025 Jun 11;33(6):941-956.e10. PMID: 40446807 -
Cancer Res
A RIPK3-PGE2 Circuit Mediates Myeloid-Derived Suppressor Cell-Potentiated Colorectal Carcinogenesis. [Abstract]2018 Oct 1;78(19):5586-5599. PMID: 30012671 -
Nat Commun
2026 May 7. PMID: 42098128 -
Nat Commun
2025 May 30;16(1):5006. PMID: 40442064 -
Nat Commun
THBS1-producing tumor-infiltrating monocyte-like cells contribute to immunosuppression and metastasis in colorectal cancer. [Abstract]2023 Sep 25;14(1):5534. PMID: 37749092 -
Cell Death Differ
Cell death-induced release of the pro-aging protein acyl CoA binding protein (ACBP) into the circulation. [Abstract]2026 Jun 3. PMID: 42236908 -
Adv Sci (Weinh)
2026 Feb 3:e16660. PMID: 41632021 -
Adv Sci (Weinh)
PRMT5 Inhibitor Synergizes with Chemotherapy to Induce Resembling Mismatch Repair Deficiency and Enhance Anti-TIGIT Therapy in Microsatellite-Stable Colorectal Cancer. [Abstract]2025 May 8:e2500271. PMID: 40344511 -
Adv Sci (Weinh)
2025 Jan 31:e2408845. PMID: 39888307 -
Adv Sci (Weinh)
DNMT3a Downregulation Ttriggered Upregulation of GABAA Receptor in the mPFC Promotes Paclitaxel-Induced Pain and Anxiety in Male Mice. [Abstract]2024 Dec 16:e2407387. PMID: 39679872 -
Adv Sci (Weinh)
YY2/BUB3 Axis promotes SAC Hyperactivation and Inhibits Colorectal Cancer Progression via Regulating Chromosomal Instability. [Abstract]2024 Jul;11(26):e2308690. PMID: 38682484 -
Adv Sci (Weinh)
Micro-Engineered Organoid-on-a-Chip Based on Mesenchymal Stromal Cells to Predict Immunotherapy Responses of HCC Patients. [Abstract]2023 Sep;10(27):e2302640. PMID: 37485650 -
Adv Sci (Weinh)
Inhibition of CDK1 Overcomes Oxaliplatin Resistance by Regulating ACSL4-mediated Ferroptosis in Colorectal Cancer. [Abstract]2023 Sep;10(25):e2301088. PMID: 37428466 -
-
-
Biomaterials
Immune modulation of the liver metastatic colorectal cancer microenvironment via the oral CAPOX-mediated cGAS-STING pathway. [Abstract]2024 Oct:310:122625. PMID: 38820768 -
J Exp Clin Cancer Res
Pyrotinib targeted EGFR/GRP78 mediated cell apoptosis in high EGFR gene copy number gastric cancer. [Abstract]2025 Aug 19;44(1):245. PMID: 40830980 -
J Exp Clin Cancer Res
Overcoming high level adenosine-mediated immunosuppression by DZD2269, a potent and selective A2aR antagonist. [Abstract]2022 Oct 14;41(1):302. PMID: 36229853 -
J Exp Clin Cancer Res
Pharmacological targeting PTK6 inhibits the JAK2/STAT3 sustained stemness and reverses chemoresistance of colorectal cancer. [Abstract]2021 Sep 22;40(1):297. PMID: 34551797 -
J Exp Clin Cancer Res
miR-19b-3p promotes colon cancer proliferation and oxaliplatin-based chemoresistance by targeting SMAD4: validation by bioinformatics and experimental analyses. [Abstract]2017 Sep 22;36(1):131. PMID: 28938919 -
J Nanobiotechnology
Oxygen vacancy-engineered bimetallic nanozymes for disrupting electron transport chain and synergistic multi-enzyme activity to reverse oxaliplatin resistance in colorectal cancer. [Abstract]2025 May 16;23(1):352. PMID: 40380190 -
J Nanobiotechnology
Photoacoustic mediated multifunctional tumor antigen trapping nanoparticles inhibit the recurrence and metastasis of ovarian cancer by enhancing tumor immunogenicity. [Abstract]2022 Nov 3;20(1):468. PMID: 36329515 -
Cell Discov
Single-cell profiling reveals molecular basis of malignant phenotypes and tumor microenvironments in small bowel adenocarcinomas. [Abstract]2022 Sep 14;8(1):92. PMID: 36104333 -
Redox Biol
p53 and fatty acids collaborate to trigger ferroptosis via the FBXO2-FABP5 axis in colorectal cancer. [Abstract]2026 Mar:90:104043. PMID: 41604941 -
Redox Biol
Redistribution of defective mitochondria-mediated dihydroorotate dehydrogenase imparts 5-fluorouracil resistance in colorectal cancer. [Abstract]2024 May 23:73:103207. PMID: 38805974 -
J Control Release
Oxygen and oxaliplatin-loaded nanoparticles combined with photo-sonodynamic inducing enhanced immunogenic cell death in syngeneic mouse models of ovarian cancer. [Abstract]2021 Apr 10:332:448-459. PMID: 33662456 -
Gut Microbes
Fusobacterium nucleatum induces chemoresistance in colorectal cancer by inhibiting pyroptosis via the Hippo pathway. [Abstract]2024 Jan-Dec;16(1):2333790. PMID: 38533566 -
MedComm (2020)
Gallium complex K6 inhibits colorectal cancer by increasing ROS levels to induce DNA damage and enhance phosphatase and tensin homolog activity. [Abstract]2024 Jul 24;5(8):e665. PMID: 39049965 -
Cell Rep Med
Sex-biased intratumoral microbiome influences tumor molecular and immune landscape and disease outcomes. [Abstract]2026 May 19;7(5):102757. PMID: 42013847 -
Cell Rep Med
Enhancing gastric cancer immunotherapy: Insights from multi-omics analysis and innovations in photodynamic-chemotherapy nanoplatforms. [Abstract]2026 Mar 17;7(3):102635. PMID: 41747719 -
J Immunother Cancer
Memory B cell subset shapes antitumor immunity and response to PD-1 blockade in mismatch repair-deficient colorectal cancers. [Abstract]2026 Jan 8;14(1):e012121. PMID: 41506788 -
J Immunother Cancer
2025 Nov 19;13(11):e012652. PMID: 41260904 -
Cell Rep Med
CAN-Scan: A multi-omic phenotype-driven precision oncology platform identifies prognostic biomarkers of therapy response for colorectal cancer. [Abstract]2025 Apr 2:102053. PMID: 40187357 -
J Immunother Cancer
Hyperbaric oxygen facilitates teniposide-induced cGAS-STING activation to enhance the antitumor efficacy of PD-1 antibody in HCC. [Abstract]2022 Aug;10(8):e004006. PMID: 36002188 -
J Exp Med
2018 Jan 2;215(1):115-140. PMID: 29191914 -
Pharmacol Res
CDC7 stabilized by KRAS signaling reactivation impairs chemosensitivity in KRAS-mutant colorectal cancer. [Abstract]2025 Dec:222:108027. PMID: 41207349 -
Pharmacol Res
2024 May 9:204:107208. PMID: 38729587 -
Cancer Lett
2026 Jan 28:638:218156. PMID: 41265630 -
Cancer Lett
Tumor-derived CCL5 recruits CCR1+ macrophages to suppress apoptosis and drive proliferation in duodenal adenocarcinoma. [Abstract]2025 Sep 25:634:218064. PMID: 41015267 -
Cancer Lett
Traditional medicine Bazi Bushen potentiates immunosurveillance of senescent liver cancer cells via cGAS-STING signaling activation in macrophages. [Abstract]2025 Feb 8:217544. PMID: 39929434 -
Cancer Lett
The CAIX inhibitor SLC-0111 exerts anti-cancer activity on gastric cancer cell lines and resensitizes resistant cells to 5-Fluorouracil, taxane-derived, and platinum-based drugs. [Abstract]2023 Sep 1:571:216338. PMID: 37549770 -
Cancer Lett
De novo pyrimidine synthesis fuels glycolysis and confers chemoresistance in gastric cancer. [Abstract]2022 Nov 28:549:215837. PMID: 35921972 -
Cancer Lett
IRE1α-targeting downregulates ABC transporters and overcomes drug resistance of colon cancer cells. [Abstract]2020 Apr 28;476:67-74. PMID: 32061752 -
Int J Biol Sci
2022 May 21;18(9):3747-3761. PMID: 35813474 -
Cell Death Dis
The EHMT2-MBLAC2 axis suppresses ribosomal DNA transcription in response to nucleolar DNA damage. [Abstract]2026 Mar 18;17(1):320. PMID: 41851073 -
Adv Healthc Mater
Decellularized Extracellular Matrix Scaffolds to Engineer the Dormant Landscape of Microscopic Colorectal Cancer Liver Metastasis. [Abstract]2025 Oct 13:e01791. PMID: 41083747 -
Cell Death Dis
Chemotherapy-induced macrophage CXCL7 expression drives tumor chemoresistance via the STAT1/PHGDH-serine metabolism axis and SAM paracrine feedback to M2 polarization. [Abstract]2025 May 14;16(1):379. PMID: 40368902 -
Cell Death Dis
Mitochondrial, metabolic and bioenergetic adaptations drive plasticity of colorectal cancer cells and shape their chemosensitivity. [Abstract]2025 Apr 5;16(1):253. PMID: 40185729 -
Cell Death Dis
2025 Apr 14;16(1):293. PMID: 40229252 -
Cell Death Dis
Inhibition of KLF5 promotes ferroptosis via the ZEB1/HMOX1 axis to enhance sensitivity to oxaliplatin in cancer cells. [Abstract]2025 Jan 18;16(1):28. PMID: 39827156 -
Cell Death Dis
Hypermethylation of CDKN2A CpG island drives resistance to PRC2 inhibitors in SWI/SNF loss-of-function tumors. [Abstract]2024 Nov 5;15(11):794. PMID: 39500892 -
Cell Death Dis
Upregulation of CRABP2 by TET1-mediated DNA hydroxymethylation attenuates mitochondrial apoptosis and promotes oxaliplatin resistance in gastric cancer. [Abstract]2022 Oct 4;13(10):848. PMID: 36195596 -
Acta Biomater
Metal-organic framework-mediated multifunctional nanoparticles for combined chemo-photothermal therapy and enhanced immunotherapy against colorectal cancer. [Abstract]2022 May;144:132-141. PMID: 35307591 -
Cell Death Dis
ECHS1, an interacting protein of LASP1, induces sphingolipid-metabolism imbalance to promote colorectal cancer progression by regulating ceramide glycosylation. [Abstract]2021 Oct 6;12(10):911. PMID: 34615856 -
Cell Death Dis
MCT1 relieves osimertinib-induced CRC suppression by promoting autophagy through the LKB1/AMPK signaling. [Abstract]2019 Aug 13;10(8):615. PMID: 31409796 -
Cell Death Dis
YAP-dependent ubiquitination and degradation of β-catenin mediates inhibition of Wnt signalling induced by Physalin F in colorectal cancer. [Abstract]2018 May 22;9(6):591. PMID: 29789528 -
Proc Natl Acad Sci U S A
Inhibition of α9α10 nicotinic acetylcholine receptors prevents chemotherapy-induced neuropathic pain. [Abstract]2017 Mar 7;114(10):E1825-E1832. PMID: 28223528 -
-
Cell Commun Signal
Transcriptional deregulation by FOXM1-JUP signaling confers dual oncogenic drivers for pancreatic tumorigenesis and therapeutic resistance. [Abstract]2025 Nov 27;23(1):513. PMID: 41310714 -
Cell Commun Signal
Activation of mechanosensitive ion channel Piezo1 linking metabolic reprogramming and pro-inflammatory responses in hepatocellular carcinoma. [Abstract]2025 Jun 13;23(1):280. PMID: 40514668 -
-
-
Acta Pharmacol Sin
Calcipotriol abrogates cancer-associated fibroblast-derived IL-8-mediated oxaliplatin resistance in gastric cancer cells via blocking PI3K/Akt signaling. [Abstract]2023 Jan;44(1):178-188. PMID: 35676532 -
Acta Pharmacol Sin
Osimertinib successfully combats EGFR-negative glioblastoma cells by inhibiting the MAPK pathway. [Abstract]2021 Jan;42(1):108-114. PMID: 32398685 -
Phytomedicine
Huangqi Guizhi Wuwu decoction alleviate Oxaliplatin-Induced Peripheral Neuropathy by adjusting the myelin regeneration. [Abstract]2025 Sep:145:157039. PMID: 40618490 -
Phytomedicine
Erianin triggers ferroptosis in colorectal cancer cells by facilitating the ubiquitination and degradation of GPX4. [Abstract]2025 Apr:139:156465. PMID: 39938177 -
Phytomedicine
Gegen Qinlian Decoction reverses oxaliplatin resistance in colorectal cancer by inhibiting YTHDF1-regulated m6A modification of GLS1. [Abstract]2024 Jul 25:133:155906. PMID: 39089089 -
Phytomedicine
Compound-composed Chinese medicine of Huachansu triggers apoptosis of gastric cancer cells through increase of reactive oxygen species levels and suppression of proteasome activities. [Abstract]2024 Jan:123:155169. PMID: 37992493 -
ACS Appl Mater Interfaces
Primary Human Gastric Cancer Cells Integrated Hydrogel Microcapsules for Personalized Drug Screening. [Abstract]2026 Feb 11;18(5):7900-7909. PMID: 41615381 -
Apoptosis
Nicotine suppresses ferroptosis in colon cancer cells via HMOX1/NF-κB pathway to reduce oxaliplatin sensitivity. [Abstract]2026 Mar 19;31(3):102. PMID: 41851365 -
Neoplasia
MYH knockdown in pancreatic cancer cells creates an exploitable DNA repair vulnerability. [Abstract]2025 Feb 11:61:101138. PMID: 39938155 -
J Transl Med
Fusobacterium nucleatum enhances oxaliplatin resistance in colon cancer by increasing PVT1 expression. [Abstract]2025 Oct 16;23(1):1112. PMID: 41102802 -
Biomed Pharmacother
Synergistic enhancement of anticancer effects by periodontal ligament stem cell exosomes and oxaliplatin via apoptosis induction and protein modulation. [Abstract]2025 Aug 19:191:118481. PMID: 40834748 -
Biomed Pharmacother
Expediting the development of robust 5-FU-resistant colorectal cancer models using innovative combined in vivo and in vitro strategies. [Abstract]2024 Nov:180:117576. PMID: 39442235 -
Biomed Pharmacother
Rupatadine inhibits colorectal cancer cell proliferation through the PIP5K1A/Akt/CDK2 pathway. [Abstract]2024 Jun 4:176:116826. PMID: 38838507 -
Biomed Pharmacother
Nanocarrier mediated entinostat and oxaliplatin combination therapy displayed enhanced efficacy against pancreatic cancer. [Abstract]2024 May 16:175:116743. PMID: 38759290 -
Biomed Pharmacother
Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. [Abstract]2023 Jul:163:114751. PMID: 37105073 -
Biomed Pharmacother
Mitochondrial DNA content reduction induces aerobic glycolysis and reversible resistance to drug-induced apoptosis in SW480 colorectal cancer cells. [Abstract]2018 Jul:103:729-737. PMID: 29684851 -
Oncogene
USP10-mediated Ku70/80 stabilization inhibits PANoptosis and promotes chemoresistance in colorectal cancer. [Abstract]2025 Sep 18. PMID: 40968255 -
Oncogene
Aberrant FAM135B attenuates the efficacy of chemotherapy in colorectal cancer by modulating SRSF1-mediated alternative splicing. [Abstract]2024 Nov;43(48):3532-3544. PMID: 39397154 -
Cell Chem Biol
Pharmacological Targeting of Vacuolar H+-ATPase via Subunit V1G Combats Multidrug-Resistant Cancer. [Abstract]2020 Nov 19;27(11):1359-1370.e8. PMID: 32649904 -
Cell Rep
Pharmacological boosting of cGAS activation sensitizes chemotherapy by enhancing antitumor immunity. [Abstract]2023 Mar 20;42(3):112275. PMID: 36943864 -
Cell Rep
Redox-sensitive cyclophilin A elicits chemoresistance through realigning cellular oxidative status in colorectal cancer. [Abstract]2021 Nov 30;37(9):110069. PMID: 34852234 -
J Med Chem
Selective Penicillamine Substitution Enables Development of a Potent Analgesic Peptide that Acts through a Non-Opioid-Based Mechanism. [Abstract]2021 Jul 8;64(13):9271-9278. PMID: 34142837 -
J Med Chem
Development of Conformationally Constrained α-RgIA Analogues as Stable Peptide Antagonists of Human α9α10 Nicotinic Acetylcholine Receptors. [Abstract]2020 Aug 13;63(15):8380-8387. PMID: 32597184 -
Int J Nanomedicine
SiRNF8 Delivered by DNA Framework Nucleic Acid Effectively Sensitizes Chemotherapy in Colon Cancer. [Abstract]2024 Jan 6:19:171-188. PMID: 38204601 -
Int J Nanomedicine
The Destruction Of Laser-Induced Phase-Transition Nanoparticles Triggered By Low-Intensity Ultrasound: An Innovative Modality To Enhance The Immunological Treatment Of Ovarian Cancer Cells. [Abstract]2019 Dec 2;14:9377-9393. PMID: 31819438 -
Oncogenesis
NFATc1-mediated activation of the pentose phosphate pathway and cell cycle dysregulation collectively drive tumor progression. [Abstract]2025 Nov 7;14(1):39. PMID: 41203626 -
Mol Med
Knockdown of SLC7A5 inhibits malignant progression and attenuates oxaliplatin resistance in gastric cancer by suppressing glycolysis. [Abstract]2025 Mar 25;31(1):115. PMID: 40133832 -
J Cell Biol
2023 Jan 2;222(1):e202202110. PMID: 36282216 -
Cell Biosci
2025 Jul 4;15(1):95. PMID: 40615893 -
Cell Biosci
MIIP downregulation drives colorectal cancer progression through inducing peri-cancerous adipose tissue browning. [Abstract]2024 Jan 20;14(1):12. PMID: 38245780 -
Ecotoxicol Environ Saf
PPARγ-responsive luciferase reporter system for high-throughput screening of chemical toxins with potential pulmonary fibrosis effects. [Abstract]2025 Nov 15:307:119433. PMID: 41273832 -
Biomater Adv
Thermosensitive nanogel-based oxaliplatin delivery system for synergistic intratumoral radiofrequency chemotherapy. [Abstract]2026 May:182:214726. PMID: 41581319 -
Biomater Adv
Mesenchymal stem cell-derived small extracellular vesicles loaded with miRNA-4488 alleviate chemotherapy-induced premature ovarian insufficiency via mitigation of apoptosis and oxidative stress. [Abstract]2025 Dec 11:181:214656. PMID: 41406654 -
Cancer Cell Int
Establishment and characteristic analysis of a novel patient derived cell line of intrahepatic cholangiocarcinoma. [Abstract]2025 Oct 15;25(1):357. PMID: 41094661 -
Cancer Cell Int
Identification of E3 ubiquitin ligase-based molecular subtypes and prognostic signature regarding prognosis and immune landscape in bladder cancer. [Abstract]2025 Feb 27;25(1):70. PMID: 40016750 -
Eur J Med Chem
2021 Jan 15;210:113080. PMID: 33310286 -
Int J Mol Med
Exportin 1 inhibitor KPT‑330 reverses oxaliplatin resistance via p53 nuclear retention in colorectal cancer. [Abstract]2026 Jan;57(1):4. PMID: 41133455 -
Biosensors (Basel)
FAP-Anchored Retinoic Acid Nanoparticles for Stromal Reprogramming and Enhanced Intratumoral Oxaliplatin Delivery in Fibrotic Colorectal Tumours. [Abstract]2026 Mar 25;16(4):189. PMID: 42041410 -
Biochem Pharmacol
Discovery of a potent BRD4 PROTAC and evaluation of its bioactivity in breast cancer cell lines. [Abstract]2025 Jul 12:241:117159. PMID: 40659131 -
Mol Cancer Ther
Functional genomics and proteomics identify Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in diverse T-cell lymphoma models. [Abstract]2026 Jun 13. PMID: 42295240 -
Mol Cancer Ther
Mosperafenib, a novel paradox breaker BRAF inhibitor with potent preclinical activity in BRAF mutated colorectal cancer. [Abstract]2025 Dec 4. PMID: 41340484 -
Mol Cancer Ther
PIN1 Inhibition Sensitizes Chemotherapy in Gastric Cancer Cells by Targeting Stem Cell-like Traits and Multiple Biomarkers. [Abstract]2020 Mar;19(3):906-919. PMID: 31879364 -
J Ethnopharmacol
Overcoming multi drug resistance mediated by ABC transporters by a novel acetogenin- annonacin from Annona muricata L. [Abstract]2024 Mar 25:322:117598. PMID: 38113989 -
Mar Drugs
Ascomylactam C Induces an Immunogenic Cell Death Signature via Mitochondria-Associated ER Stress in Lung Cancer and Melanoma. [Abstract]2023 Nov 21;21(12):600. PMID: 38132921 -
Mol Ther Oncol
A KRASG12V-targeted bispecific T cell engager promotes immunity against colorectal solid tumor. [Abstract]2025 Nov 22;33(4):201098. PMID: 41438133 -
Cells
Machine Learning-Driven Multi-Omics Analysis Identifies CHP2 as a Key PANoptosis-Related Dual-Function Biomarker in Colorectal Cancer. [Abstract]2026 Feb 28;15(5):430. PMID: 41827864 -
Cells
RgIA4 Prevention of Acute Oxaliplatin-Induced Cold Allodynia Requires α9-Containing Nicotinic Acetylcholine Receptors and CD3+ T-Cells. [Abstract]2022 Nov 11;11(22):3561. PMID: 36428990 -
-
Commun Biol
Development and validation of the Normalized Organoid Growth Rate (NOGR) metric in brightfield imaging-based assays. [Abstract]2024 Dec 3;7(1):1612. PMID: 39627437 -
Precis Clin Med
Agrimol B inhibits pancreatic ductal adenocarcinoma by induction of lethal mitophagy through decreasing mitochondrial transcription termination factor 3. [Abstract]2026 Mar 14;9(2):pbag009. PMID: 41978696 -
Int J Mol Sci
LRRC8A Inhibition Overcomes Chemoresistance by Downregulating MRP3 and CYP3A4 in the 3D Spheroid Model of Human Breast Cancer Cells. [Abstract]2026 Mar 13;27(6):2646. PMID: 41898509 -
Int J Mol Sci
Gene Expression Profiling of Pancreatic Ductal Adenocarcinoma Cells in Hypercapnia Identifies SIAH3 as a Novel Prognostic Biomarker. [Abstract]2025 Mar 21;26(7):2848. PMID: 40243415 -
Biol Direct
Integrative genomics unveils basement membrane-related diagnostic markers and therapeutic targets in esophageal squamous cell carcinoma. [Abstract]2024 Sep 11;19(1):79. PMID: 39256753 -
Int J Mol Sci
Proteomic Profiling of Chemotherapy Responses in FOLFOX-Resistant Colorectal Cancer Cells. [Abstract]2023 Jun 8;24(12):9899. PMID: 37373047 -
Int J Oncol
2022 Nov;61(5):139. PMID: 36169178 -
Int Immunopharmacol
A novel Senescence-Based prognostic model unveils tumor interactions and drug resistance in colorectal cancer. [Abstract]2024 May 10:134:112197. PMID: 38733826 -
Eur J Pharmacol
Compound Z526 alleviates chemotherapy-induced cachectic muscle loss by ameliorating oxidative stress-driven protein metabolic imbalance and apoptosis. [Abstract]2024 Jul 5:974:176538. PMID: 38552940 -
Int J Cancer
Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells. [Abstract]2020 Mar 15;146(6):1700-1716. PMID: 31381140 -
Mol Oncol
Patient therapy outcome modeling in cancer organoids is improved by cancer-associated fibroblasts and organoid assembly convolution. [Abstract]2026 Jun 5. PMID: 42246237 -
Mol Oncol
Optimized low-dose combinatorial drug treatment boosts selectivity and efficacy of colorectal carcinoma treatment. [Abstract]2020 Nov;14(11):2894-2919. PMID: 33021054
Oxaliplatin purchased from MedChemExpress. Usage Cited in: Mol Oncol. 2020 Nov;14(11):2894-2919. [Abstract]
FOLFOX was administered as 6 mg/kg Oxaliplatin two hours before administration of 90 mg/kg Leucovorin and 50 mg/kg 5-Fluorouracil at day 1 and a repeat of 5‐Fluorouracil dosing on day 2. Weight loss of ODC-, CTRL-, and FOLFOX-treated mice over time of mice with DLD1 tumors.
-
Cancers (Basel)
In Vitro and In Silico Investigation of BCI Anticancer Properties and Its Potential for Chemotherapy-Combined Treatments. [Abstract]2023 Sep 6;15(18):4442. PMID: 37760412 -
Clin Epigenetics
Identification of hepatocellular carcinoma subtypes based on PcG-related genes and biological relevance with cancer cells. [Abstract]2022 Dec 24;14(1):184. PMID: 36566204 -
Cancers (Basel)
HuR Plays a Role in Double-Strand Break Repair in Pancreatic Cancer Cells and Regulates Functional BRCA1-Associated-Ring-Domain-1(BARD1) Isoforms. [Abstract]2022 Apr 6;14(7):1848. PMID: 35406624 -
ACS Omega
A LRELHLNNN-Gal‑3 Modified Adipose Decellularized Scaffold To Construct Colorectal Cancer Model for Anticancer Drug Screening and Immunotherapy. [Abstract]2025 Oct 30;10(44):52931-52943. PMID: 41244442 -
Pharm Res
Active Targeting of Colorectal Cancer Using Chemotherapy-Loaded Nanoparticles Functionalized with a Folate Receptor-α (FRα) Ligand, Pemetrexed. [Abstract]2025 Nov 18. PMID: 41254319 -
Cancer Sci
D-1553: A novel KRASG12C inhibitor with potent and selective cellular and in vivo antitumor activity. [Abstract]2023 Jul;114(7):2951-2960. PMID: 37158138 -
FEBS J
The sulfonamide anticancer agent indisulam enhances the chemosensitivity of gastric cancer cells by targeting FKBP8. [Abstract]2026 Mar 20. PMID: 41860182 -
FEBS J
Oxaliplatin accelerates immunogenic cell death by activating the cGAS/STING/TBK1/IRF5 pathway in gastric cancer. [Abstract]2025 Apr 22. PMID: 40260556 -
Bioengineered
2022 Mar;13(3):6688-6697. PMID: 35235756 -
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Transl Oncol
Triptonide stabilizes BIM to enhance oxaliplatin-induced ferroptosis and apoptosis in colorectal cancer. [Abstract]2025 Oct:60:102491. PMID: 40773827 -
iScience
Screening and molecular mechanism research on bile microRNAs associated with chemotherapy efficacy in perihilar cholangiocarcinoma. [Abstract]2024 Dec 4;27(12):111437. PMID: 39717085 -
Neurochem Int
Repeated administration of esketamine ameliorates mechanical allodynia in mice with chemotherapy-induced peripheral neuropathy: A role of gut microbiota and metabolites. [Abstract]2025 May:185:105961. PMID: 40054499 -
Front Cell Neurosci
RgIA4 Potently Blocks Mouse α9α10 nAChRs and Provides Long Lasting Protection against Oxaliplatin-Induced Cold Allodynia. [Abstract]2017 Jul 21:11:219. PMID: 28785206 -
Sci Rep
Targeting colorectal cancer with pyrazolo[4,3-e][1,2,4]triazine and pyrazolo[4,3-e]tetrazolo[1,5-b][1,2,4]triazine sulfonamides: comprehensive in vitro evaluation. [Abstract]2026 May 31. PMID: 42225755 -
Sci Rep
Chemotherapy-derived DAMPs drive reprogramming of tumor-associated macrophages toward a pro-inflammatory phenotype in hepatocellular carcinoma. [Abstract]2026 Apr 3;16(1):17440. PMID: 41933190 -
Sci Rep
miR-340 reverses chemotherapy resistance in colon cancer via the PDCD4/WNT/β-catenin signalling pathway. [Abstract]2025 Sep 29;15(1):33421. PMID: 41022995 -
Sci Rep
Biological and genetic characterization of a newly established human primary multidrug-resistant distal cholangiocarcinoma cell line, CBC3T-6. [Abstract]2024 Nov 29;14(1):29661. PMID: 39613883 -
Sci Rep
Nrf2 inhibition increases sensitivity to chemotherapy of colorectal cancer by promoting ferroptosis and pyroptosis. [Abstract]2023 Sep 1;13(1):14359. PMID: 37658132 -
Oncol Rep
Cryopreserved biopsy tissues of rectal cancer liver metastasis for assessment of anticancer drug response in vitro and in vivo. [Abstract]2020 Feb;43(2):405-414. PMID: 31894341 -
Sci Rep
Shikonin induces mitochondria-mediated apoptosis and enhances chemotherapeutic sensitivity of gastric cancer through reactive oxygen species. [Abstract]2016 Dec 1;6:38267. PMID: 27905569 -
Clin Immunol
Integrated analysis of tumour-derived exosome-related immune genes to predict progression and immune status of hepatocellular carcinoma. [Abstract]2023 Nov:256:109774. PMID: 37774907 -
Cancer Res Treat
Establishment of Patient-Derived Organoids Using Ascitic or Pleural Fluid from Cancer Patients. [Abstract]2023 Oct;55(4):1077-1086. PMID: 37309112 -
ACS Pharmacol Transl Sci
T‑Cell Immunoreceptor with Ig and Immunoreceptor Tyrosine-Based Inhibitory Motif Domains/Cluster of Differentiation 40 Cellular Nanovesicles Carrying Oxaliplatin Exhibited Superior Pancreatic Cancer Cells Therapy. [Abstract]2026 Mar 28;9(4):1010-1020. PMID: 41988365 -
Biochim Biophys Acta Mol Cell Res
Reduced store operated calcium entry contributes to autophagy mediated escape of prostate cancer to oxaliplatin treatment. [Abstract]2025 Apr 4:119953. PMID: 40189057 -
ACS Pharmacol Transl Sci
α9-Containing Nicotinic Acetylcholine Receptors Are Required for RgIA-5474 Attenuation of Chemotherapy-Induced Neuropathic Pain. [Abstract]2024 Nov 12;7(12):3935-3944. PMID: 39698293 -
Biochim Biophys Acta Mol Cell Res
DHRS2-induced SPHK1 downregulation contributes to the cell growth inhibition by Trichothecin in colorectal carcinoma. [Abstract]2024 Sep 14:119846. PMID: 39284549 -
Digestion
KIF4A Facilitates Oxaliplatin Resistance and Stemness in Colon Cancer by Boosting Glucose Metabolism. [Abstract]2025 Mar 27:1-19. PMID: 40147432 -
Heliyon
2023 Jun 1;9(6):e16872. PMID: 37313175 -
Heliyon
The potential effects and mechanisms of Gegen Qinlian Decoction in oxaliplatin-resistant colorectal cancer based on network pharmacology. [Abstract]2022 Oct 30;8(11):e11305. PMID: 36353164 -
Exp Cell Res
Network-based analysis with primary cells reveals drug response landscape of acute myeloid leukemia. [Abstract]2020 Aug 1;393(1):112054. PMID: 32376287 -
J Gastroenterol Hepatol
IKZF3 Promotes Gastric cancer Progression and Oxaliplatin Resistance via PI3K/AKT/mTOR Activation. [Abstract]2026 Mar 12. PMID: 41820205 -
BMC Cancer
Individualized drug screening in cholangiocarcinoma using organoid models and patient-derived tumor xenograft. [Abstract]2025 Dec 31. PMID: 41469951 -
BMC Cancer
A quinoline-2-thione derivative as a novel chemotherapy drug candidate displays anti-tumor activity in vitro and in vivo. [Abstract]2024 Oct 13;24(1):1272. PMID: 39397012 -
Stem Cells Int
lncRNA TUG1 Facilitates Colorectal Cancer Stem Cell Characteristics and Chemoresistance by Enhancing GATA6 Protein Stability. [Abstract]2021 Nov 23:2021:1075481. PMID: 34858502 -
Front Oncol
Patient-Derived Xenograft Models for Intrahepatic Cholangiocarcinoma and Their Application in Guiding Personalized Medicine. [Abstract]2021 Jul 13:11:704042. PMID: 34327143 -
Dalton Trans
Oxaliplatin and [Pt(R,R-DACH)(panobinostat-2H)] show nanomolar cytotoxicity towards diffuse intrinsic pontine glioma (DIPG). [Abstract]2020 May 7;49(17):5703-5710. PMID: 32297619 -
Pathol Res Pract
SIRT3 promotes oxaliplatin sensitivity in hepatocellular carcinoma by promoting ferroptosis through endoplasmic reticulum stress response. [Abstract]2026 May:281:156400. PMID: 41775211 -
Pathol Res Pract
ETV4 promotes the growth, metastasis, glycolysis, and oxaliplatin resistance of colorectal cancer by transcription activation-mediated SLC38A5 upregulation. [Abstract]2025 May 21:271:156033. PMID: 40435908 -
Mol Carcinog
Potential Value of AURKA and CDK6 Amplification for the Response of Patients With Gastric Cancer to Neoadjuvant Chemotherapy. [Abstract]2025 Apr 13. PMID: 40222043 -
J Inorg Biochem
Bridging pyrimidine hemicurcumin and Cisplatin: Synthesis, coordination chemistry, and in vitro activity assessment of a novel Pt(II) complex. [Abstract]2024 Aug 19:260:112702. PMID: 39163714 -
Mol Carcinog
Down-regulation of aquaporin 5-mediated epithelial-mesenchymal transition and anti-metastatic effect by natural product Cairicoside E in colorectal cancer. [Abstract]2017 Dec;56(12):2692-2705. PMID: 28833571 -
Naunyn Schmiedebergs Arch Pharmacol
Enhancing sensitivity to oxaliplatin in tongue squamous cell carcinoma: mechanistic insights and therapeutic potential of DHA combination therapy. [Abstract]2025 Apr;398(4):4393-4407. PMID: 39476243 -
Hum Cell
Exosomal circ_0091741 promotes gastric cancer cell autophagy and chemoresistance via the miR-330-3p/TRIM14/Dvl2/Wnt/β-catenin axis. [Abstract]2023 Jan;36(1):258-275. PMID: 36323918 -
Mol Biol Rep
FADS2 inhibits colorectal cancer cell proliferation by regulating ferroptosis through SLC7A11/GPX4. [Abstract]2025 Apr 15;52(1):394. PMID: 40232565 -
J Cancer Res Clin Oncol
Cystatin SA attenuates gastric cancer cells growth and increases sensitivity to oxaliplatin via PI3K/AKT signaling pathway. [Abstract]2024 May 8;150(5):244. PMID: 38717526 -
PLoS One
Reducing OGT and O-GlcNAcylation enhance the anticancer effects of oxaliplatin in SW620 metastatic colorectal cancer cells. [Abstract]2026 Feb 10;21(2):e0341971. PMID: 41666153 -
Int J Immunopathol Pharmacol
Chemotherapy elevates cell surface PD-L1 and MHC-I expression in apoptotic gastric cancer cells. [Abstract]2025 Jan-Dec:39:3946320251338662. PMID: 40380807 -
Photodiagnosis Photodyn Ther
The role of autophagy in the treatment of colon cancer by chlorin e6 photodynamic therapy combined with oxaliplatin. [Abstract]2022 Dec:40:103082. PMID: 36028170 -
World J Gastrointest Oncol
Interleukin-22 promotes cancer stemness and chemotherapy resistance in colorectal cancer via epidermal growth factor receptor/extracellular signal-regulated kinase pathway. [Abstract]2025 Aug 15;17(8):108535. PMID: 40837778 -
In Vitro Model
Colorectal carcinoma organoid and cancer-associated fibroblasts co-culture system for drug evaluation. [Abstract]2025 Mar 5;4(1):31-44. PMID: 40160212 -
Biomol Biomed
Periplocin improves the sensitivity of oxaliplatin-resistant hepatocellular carcinoma cells by inhibiting M2 macrophage polarization. [Abstract]2025 Mar 7;25(4):857-868. PMID: 39207178 -
Biochem Biophys Res Commun
Non-cytotoxic nanomolar concentration of arctigenin protects neuronal cells from chemotherapy-induced ferroptosis by regulating SLC7A11-cystine-cysteine axis. [Abstract]2024 May 28:710:149895. PMID: 38593620 -
Biochem Biophys Res Commun
2023 Jan 1:638:94-102. PMID: 36442237 -
Biochem Biophys Res Commun
The tyrosine phosphatase SHP2 promotes proliferation and oxaliplatin resistance of colon cancer cells through AKT and ERK. [Abstract]2021 Jul 23:563:1-7. PMID: 34052504 -
Cancer Rep
2025 Dec;8(12):e70401. PMID: 41308696 -
Biol Pharm Bull
Ginsenoside Rg3 Combined with Oxaliplatin Inhibits the Proliferation and Promotes Apoptosis of Hepatocellular Carcinoma Cells via Downregulating PCNA and Cyclin D1. [Abstract]2019 Jun 1;42(6):900-905. PMID: 30930425 -
Gastroenterol Res Pract
2021 Jun 17:2021:5960821. PMID: 34239555 -
-
-
-
-
-
-
-
bioRxiv
Integrating functional genomics and proteomics identifies Folate Carrier SLC19A1 as a predictor of pralatrexate sensitivity in T-cell lymphoma. [Abstract]2025 Oct 9:2025.10.08.681217. PMID: 41279001 -
-
-
-
bioRxiv
A whole genomic CRISPR-Cas9 screen identifies the amino acid transporter SLC43A1 (LAT3) as a major determinant of oxaliplatin sensitivity in colorectal cancer cells. [Abstract]2025 Apr 24:2025.04.21.649594. PMID: 40568133 -
-
bioRxiv
Paired primary-metastasis patient-derived organoids and mouse models identify phenotypic evolution and druggable dependencies of peritoneal metastasis from appendiceal cancer. [Abstract]2025 Feb 22:2025.02.17.638725. PMID: 40027618 -
-
-
-
-
-
-
-
Ann Transl Med
E2F1 inhibits cellular senescence and promotes oxaliplatin resistance in colorectal cancer. [Abstract]2023 Feb 28;11(4):185. PMID: 36923082 -
Oxid Med Cell Longev
Vitamin D Promotes Ferroptosis in Colorectal Cancer Stem Cells via SLC7A11 Downregulation. [Abstract]2023 Feb 16:2023:4772134. PMID: 36846715 -
-
-
-
-
-
Tumour Biol
Upregulation of CD44v6 contributes to acquired chemoresistance via the modulation of autophagy in colon cancer SW480 cells. [Abstract]2016 Jul;37(7):8811-24. PMID: 26747179
Solvant et solubilité
H2O : 2 mg/mL (5.03 mM; ultrasonic and warming and heat to 60°C; DMSO can inactivate Oxaliplatin's activity)
DMF : 1.67 mg/mL (4.20 mM; Need ultrasonic; DMSO can inactivate Oxaliplatin's activity)
Ethanol : < 1 mg/mL (insoluble; DMSO can inactivate Oxaliplatin's activity)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 5% w/v Glucose Solution
Solubility: 3.33 mg/mL (8.38 mM); Clear solution; Need ultrasonic
Pureté et documentation
-
Fiche technique (294 KB)
-
SDS (419 KB)
- English - EN (419 KB)
- Français - FR (419 KB)
- Deutsch - DE (419 KB)
- Norwegian - NO (419 KB)
- Español - ES (419 KB)
- Swedish - SV (419 KB)
- Italian - IT (419 KB)
- Portuguese - PT (419 KB)
-
Instruction de manipulation (2659 KB)
Références
[1]. Raymond E, et al. Oxaliplatin: a review of preclinical and clinical studies. Ann Oncol. 1998 Oct;9(10):1053-71. [Content Brief]
[2]. Mohammed MQ, et al. Oxaliplatin is active in vitro against human melanoma cell lines: comparison with NSC 119875 and NSC 241240. Anticancer Drugs. 2000 Nov;11(10):859-63. [Content Brief]
[3]. Pendyala L, et al. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res. 1993 Dec 15;53(24):5970-6. [Content Brief]
[4]. Wang Z, et al. Oxaliplatin induces apoptosis in hepatocellular carcinoma cells and inhibits tumor growth. Expert Opin Investig Drugs. 2009 Nov;18(11):1595-604 [Content Brief]
[5]. Mathé G, et al. Oxalato-platinum or 1-OHP, a third-generation platinum complex: an experimental and clinical appraisal and preliminary comparison with cis-platinum. Biomed Pharmacother. 1989;43(4):237-50. [Content Brief]
[6]. Schellingerhout D, et al. Impairment of retrograde neuronal transport in oxaliplatin-induced neuropathy demonstrated by molecular imaging. PLoS One. 2012;7(9):e45776. doi: 10.1371/journal.pone.0045776. Epub 2012 Sep 20. [Content Brief]
[7]. Park GY, et al. Phenanthriplatin, a monofunctional DNA-binding platinum anticancer drug candidate with unusual potency and cellular activity profile. Proc Natl Acad Sci U S A. 2012 Jul 24;109(30):11987-92. [Content Brief]
[8]. Yi Yao, et al. Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochim Biophys Acta. 2009 Oct;1794(10):1433-40. [Content Brief]
[9]. Garrett MJ, et, al. Capecitabine, Oxaliplatin, and Bevacizumab (BCapOx) Regimen for Metastatic Colorectal Cancer. Hosp Pharm. 2017 May;52(5):341-347. [Content Brief]
[10]. Jiang Y, et al. Oxaliplatin-induced neuropathic pain in cancer: animal models and related research progress. Front Pharmacol. 2025 May 30;16:1609791. [Content Brief]
[11]. Xiao WH, et al. Characterization of oxaliplatin-induced chronic painful peripheral neuropathy in the rat and comparison with the neuropathy induced by paclitaxel. Neuroscience. 2012 Feb 17;203:194-206. [Content Brief]
[12]. Dehghani S, et al. Neuroinflammatory Mechanisms and Therapeutic Targets in Oxaliplatin-Induced Peripheral Neuropathy: a Comprehensive Review. Neurotox Res. 2025 Dec 13;43(6):52. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMF / H2O | 1 mM | 2.5171 mL | 12.5853 mL | 25.1705 mL | 62.9263 mL |
| H2O | 5 mM | 0.5034 mL | 2.5171 mL | 5.0341 mL | 12.5853 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.